Clincosm LogoSign in Get a demo

Role of 18F-FDG PET/CT in Gastric Cancer

Sponsor
Sohag University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05687552
Collaborator
(none)
50
Enrollment
12
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The objective of the study is to assess the value of PET/CT in diagnosis, staging, response evaluation, and relapse monitoring of gastric cancer.

Condition or Disease Intervention/Treatment Phase
  • Device: pet -ct

Detailed Description

gastric cancer (GC) is the fifth most common malignancy and the third leading cause of cancer mortality worldwide (1) It carries a poor prognosis, with a 5-year survival of only 20%-30% (2) Clinical staging, based mainly on imaging, is critical in determining the best treatment.There is a widely accepted consensus of the usefulness of FDG PET/CT in staging and restaging of gastric cancer. According to evidence-based data, this modality can evaluate gastric cancer more accurately and is helpful for evaluation of tumor biologic characteristics, detection of lymph node and distant metastases, assessment of tumor response to therapy(9).

retrospective and prospective study will conducted at Sohag oncology hospital, nuclear medicine unit& Assuit university hospital, nuclear medicine unit including 50 patients in 12 months .

Study Design

Study Type:
Observational
Anticipated Enrollment :
50 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Role of 18F-FDG PET/CT in Gastric Cancer
Anticipated Study Start Date :
Jan 1, 2023
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Jan 1, 2024

Outcome Measures

Primary Outcome Measures

  1. comparison of pet -ct finding with ct finding [base line]

    The 18F-FDG PET/CT scan is visually estimated in the patients included in the study and quantitatively assessed by estimation of standardized uptake value(suv max). Statistical analysis of the included quantitative data.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Inclusion Criteria:

  1. patients diagnosed as GC on surgically resected specimens;

  2. Patients with gastric and extragastric metastasis.

  3. patients with gastric cancer either operated or not.

Exclusion Criteria:

  1. Patients with second malignancy.

  2. Patient without proven pathology of cancer stomach.

  3. Severely ill patient (patient with disturbed conscious level, or couldn't lay supine during the imaging).

  4. uncontrolled diabetic patient with blood glucose level more than 200mg\dl.

  5. pregnant women

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Sohag University

Investigators

  • Study Director: wafaa elmaghraby, ass prof, Sohag University
  • Study Director: mohamed soliman, prof, Sohag University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Sara Saber Ahmed, assisstant lecturer, Sohag University
ClinicalTrials.gov Identifier:
NCT05687552
Other Study ID Numbers:
  • gastric cancer
First Posted:
Jan 18, 2023
Last Update Posted:
Jan 18, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Stomach Neoplasms

Study Results

No Results Posted as of Jan 18, 2023